Statins in Chronic Kidney Disease: Cardiovascular Risk and Kidney Function

References

• . K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39(2 Suppl 1):S1–S266
   PubMed Web of Science ®Google Scholar
• . Collins AJ, Foley RN, Chavers B, . United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease and end-stage renal disease in the United States. Am J Kidney Dis. 2012;59(1 Suppl 1): A7, e1–e420
   PubMedGoogle Scholar
• . Cowie CC, Rust KF, Ford ES, . Full accounting of diabetes and prediabetes in the U.S. population in 1988–1994 and 2005–2006. Diabetes Care. 2009;32(2):287–294
   PubMed Web of Science ®Google Scholar
• . Hyre AD, Fox CS, Astor BC, Cohen AJ, Muntner P. The impact of reclassifying moderate CKD as a coronary heart disease risk equivalent on the number of US adults recommended lipid-lowering treatment. Am J Kidney Dis. 2007;49(1):37–45
   PubMedGoogle Scholar
• . Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–1305
   PubMed Web of Science ®Google Scholar
• . Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164(6):659–663
   PubMed Web of Science ®Google Scholar
• . Tonelli M, Isles C, Curhan GC, . Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation. 2004;110(12):1557–1563
   PubMedGoogle Scholar
• . Shepherd J, Kastelein JJ, Bittner V, ; TNT (Treating to New Targets) Investigators. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol. 2008;51(15):1448–1454
   PubMed Web of Science ®Google Scholar
• . Koren MJ, Davidson MH, Wilson DJ, Fayyad RS, Zuckerman A, Reed DP; ALLIANCE Investigators. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. Am J Kidney Dis. 2009;53(5):741–750
   PubMed Web of Science ®Google Scholar
• . McCullough PA, Li S, Jurkovitz CT, ; Kidney Early Evaluation Program Investigators. CKD and cardiovascular disease in screened high-risk volunteer and general populations: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999–2004. Am J Kidney Dis. 2008;51(4 Suppl 2):S38–S45
   PubMed Web of Science ®Google Scholar
• . Athyros VG, Mikhailidis DP, Papageorgiou AA, . The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol. 2004;57(7):728–734
   PubMed Web of Science ®Google Scholar
• . Colhoun HM, Betteridge DJ, Durrington PN, ; CARDS Investigators. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis. 2009;54(5):810–819
   PubMed Web of Science ®Google Scholar
• . Shepherd J, Kastelein JJ, Bittner V, . Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol. 2007;2(6):1131–1139
   PubMedGoogle Scholar
• . Rahman M, Baimbridge C, Davis BR, ; ALLHAT Collaborative Research Group. Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Kidney Dis. 2008;52(3):412–424
   PubMed Web of Science ®Google Scholar
• . Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC; Cholesterol and Recurrent Events Trial Investigators. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol. 2003;14(6):1605–1613
   PubMed Web of Science ®Google Scholar
• . Ridker PM, MacFadyen J, Cressman M, Glynn RJ. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. J Am Coll Cardiol. 2010;55(12):1266–1273
   PubMed Web of Science ®Google Scholar
• . Huskey J, Lindenfeld J, Cook T, . Effect of simvastatin on kidney function loss in patients with coronary heart disease: findings from the Scandinavian Simvastatin Survival Study (4S). Atherosclerosis. 2009;205(1):202–206
   PubMedGoogle Scholar
• . Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361(9374):2005–2016
   PubMed Web of Science ®Google Scholar
• . Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis. 2003;41(3):565–570
   PubMed Web of Science ®Google Scholar
• . Inoue T, Ikeda H, Nakamura T, . Potential benefit of statin therapy for dyslipidemia with chronic kidney disease: Fluvastatin Renal Evaluation Trial (FRET). Intern Med. 2011;50(12):1273–1278
   PubMedGoogle Scholar
• . Fassett RG, Robertson IK, Ball MJ, Geraghty DP, Coombes JS. Effect of atorvastatin on kidney function in chronic kidney disease: a randomised double-blind placebo-controlled trial. Atherosclerosis. 2010;213(1):218–224
   PubMed Web of Science ®Google Scholar
• . Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006;17(7):2006–2016
   PubMed Web of Science ®Google Scholar
• . AstraZeneca. Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease (PLANET 1). Study Results. Available at: http://clinicaltrials.gov/ct2/show/results/NCT00296374. Accessed November 25, 2013
   Google Scholar
• . AstraZeneca. Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease (PLANET II). Study Results. Available at: http://clinicaltrials.gov/ct2/show/results/NCT00296400. Accessed November 25, 2013
   Google Scholar
• . Baigent C, Landray MJ, Reith C, ; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181–2192
   PubMed Web of Science ®Google Scholar
• . Strippoli GF, Navaneethan SD, Johnson DW, . Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ. 2008;336(7645):645–651
   PubMedGoogle Scholar
• . Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GF. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;157(4):263–275
   PubMed Web of Science ®Google Scholar
• . Upadhyay A, Earley A, Lamont JL, Haynes S, Wanner C, Balk EM. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;157(4):251–262
   PubMedGoogle Scholar
• . Nikolic D, Banach M, Nikfar S, ; Lipid and Blood Pressure Meta-Analysis Collaboration Group. A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important? Int J Cardiol. 2013;168(6):5437–5447
   PubMed Web of Science ®Google Scholar
• . Oda E, Kawai R. Low-density lipoprotein (LDL) cholesterol is cross-sectionally associated with preclinical chronic kidney disease (CKD) in Japanese men. Intern Med. 2010;49(8):713–719
   PubMedGoogle Scholar
• . Schaeffner ES, Kurth T, Curhan GC, . Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol. 2003;14(8):2084–2091
   PubMed Web of Science ®Google Scholar
• . Tershakovec AM, Keane WF, Zhang Z, . Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study. Diabetes Care. 2008;31(3):445–447
   PubMedGoogle Scholar
• . Tozawa M, Iseki K, Iseki C, Oshiro S, Ikemiya Y, Takishita S. Triglyceride, but not total cholesterol or low-density lipoprotein cholesterol levels, predict development of proteinuria. Kidney Int. 2002;62(5):1743–1749
   PubMedGoogle Scholar
• . Hou W, Lv J, Perkovic V, . Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. Eur Heart J. 2013;34(24):1807–1817
   PubMed Web of Science ®Google Scholar
• . Barylski M, Nikfar S, Mikhailidis DP, ; Lipid and Blood Pressure Meta-Analysis Collaboration Group. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy-a meta-analysis of 11 randomized controlled trials involving 21,295 participants. Pharmacol Res. 2013;72:35–44
   PubMed Web of Science ®Google Scholar
• . Tonelli M, Keech A, Shepherd J, . Effect of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol. 2005;16(12):3748–3754
   PubMed Web of Science ®Google Scholar
• . Vidt DG, Ridker PM, Monyak JT, Schreiber MJ, Cressman MD. Longitudinal assessment of estimated glomerular filtration rate in apparently healthy adults: a post hoc analysis from the JUPITER study (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). Clin Ther. 2011;33(6):717–725
   PubMed Web of Science ®Google Scholar
• . Kendrick J, Shlipak MG, Targher G, Cook T, Lindenfeld J, Chonchol M. Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study. Am J Kidney Dis. 2010;55(1):42–49
   PubMedGoogle Scholar
• . Shepherd J, Barter P, Carmena R, . Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care. 2006;29(6):1220–1226
   PubMed Web of Science ®Google Scholar
• . Shepherd J, Kastelein JP, Bittner VA, ; Treating to New Targets Steering Committee and Investigators. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clin Proc. 2008;83(8):870–879
   PubMedGoogle Scholar
• . Holme I, Fayyad R, Faergeman O, ; Incremental Decrease in End Points through Aggressive Lipid Lowering Study Group. Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial. J Intern Med. 2010;267(6):567–575
   PubMedGoogle Scholar
• . McKenney JM, Davidson MH, Jacobson TA, Guyton JR, National Lipid Association Statin Safety Assessment Task Force. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol. 2006;97(8 A):89C–94C
   PubMedGoogle Scholar
• . Tsimihodimos V, Dounousi E, Siamopoulos KC. Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment. Am J Nephrol. 2008;28(6):958–973
   PubMedGoogle Scholar
• . Arici M, Walls J. End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link? Kidney Int. 2001;59(2):407–414
   PubMed Web of Science ®Google Scholar
• . Rovin BH, Tan LC. LDL stimulates mesangial fibronectin production and chemoattractant expression. Kidney Int. 1993;43(1):218–225
   PubMedGoogle Scholar
• . Coritsidis G, Rifici V, Gupta S, . Preferential binding of oxidized LDL to rat glomeruli in vivo and cultured mesangial cells in vitro. Kidney Int. 1991;39(5):858–866
   PubMedGoogle Scholar
• . Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97(12):1129–1135
   PubMed Web of Science ®Google Scholar
• . Kim SI, Kim HJ, Han DC, Lee HB. Effect of lovastatin on small GTP binding proteins and on TGF-betal and fibronectin expression. Kidney Int Suppl. 2000;77:S88–S92
   PubMedGoogle Scholar
• . Vecchione C, Gentile MT, Aretini A, . A novel mechanism of action for statins against diabetes-induced oxidative stress. Diabetologia. 2007;50(4):874–880
   PubMed Web of Science ®Google Scholar
• . Mundel P. Urinary podocytes: lost and found alive. Kidney Int. 2003;64(4):1529–1530
   PubMedGoogle Scholar
• . Nakamura T, Ushiyama C, Hirokawa K, . Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis. Nephrol Dial Transplant. 2002;17(5):798–802
   PubMed Web of Science ®Google Scholar